Research involving resistant starch (RS) is becoming more prominent. RS has the ability to modulate postprandial blood-glucose levels and can be fermented by the colonic microflora to produce short-chain fatty acids, which exert positive health benefits on the consumer such as increased colonic blood flow to ease colonic inflammation and a decreased risk of colon and/or other cancers. This paper reviews the effects of genetic manipulation on amylose levels in plants, enzymatic hydrolysis, physical treatments, chemical modifications, exposure to γ -rays, and the effects of lipid complexation on the RS content of starches from various botanical sources. All treatments reviewed increased the RS content; however, select treatments (namely genetic manipulation, enzymatic debranching, hydrothermal treatments, high hydrostatic pressure, most chemical modifications, γ -irradiation exposure, as well as lipid complexation) were more effective to varying degrees than were extrusion and mineral acid treatments. Various methods commonly used for measuring RS were compared. Additionally, the effects of food matrix components were also examined to gauge their effectiveness at inhibiting or enhancing RS formation, with lipids and gums known to be the most effective at enhancing (or apparently enhancing) RS. This review draws largely, but not exclusively, from research published post 2009.

BackgroundThe isopentenols, including isoprenol and prenol, are excellent alternative fuels. However, they are not compounds largely accumulated in natural organism. The need for the next generation of biofuels with better physical and chemical properties impels us to develop biosynthetic routes for the production of isoprenol and prenol from renewable sugar. In this study, we use the heterogenous mevalonate-dependent (MVA) isoprenoid pathway for the synthesis of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) intermediates, and then convert IPP and DMAPP to isoprenol and prenol, respectively.ResultsA mevalonate titer of 1.7 g/L was obtained by constructing an efficient MVA upper pathway in engineered E. coli. Different phosphatases and pyrophosphatases were investigated for their abilities in hydrolyzing the IPP and DMAPP. Consequently, ADP-ribose pyrophosphatase was found to be an efficient IPP and DMAPP hydrolase. Moreover, ADP-ribose pyrophosphatase from Bacillus subtilis (BsNudF) exhibited a equivalent substrate specificity towards IPP and DMAPP, while ADP-ribose pyrophosphatase from E. coli (EcNudF) presented a high substrate preference for DMAPP. Without the expression of any phosphatases or pyrophosphatases, a background level of isopentenols was synthesized. When the endogenous pyrophosphatase genes (EcNudF and yggV) that were capable of enhancing the hydrolyzation of the IPP and DMAPP were knocked out, the background level of isopentenols was still obtained. Maybe the synthesized IPP and DMAPP were hydrolyzed by some unknown hydrolases of E. coli. Finally, 1.3 g/L single isoprenol was obtained by blocking the conversion of IPP to DMAPP and employing the BsNudF, and 0.2 g/L ~80% prenol was produced by employing the EcNudF. A maximal yield of 12% was achieved in both isoprenol and prenol producing strains.ConclusionsTo the best of our knowledge, this is the first successful report on high-specificity production of isoprenol and prenol by microbial fermentation. Over 1.3 g/L isoprenol achieved in shake-flask experiments represents a quite encouraging titer of higher alcohols. In addition, the substrate specificities of ADP-ribose pyrophosphatases were determined and successfully applied for the high-specificity synthesis of isoprenol and prenol. Altogether, this work presents a promising strategy for high-specificity production of two excellent biofuels, isoprenol and prenol.

Effective therapy for Alzheimer’s disease is a major challenge in the pharmaceutical sciences. There are six FDA approved drugs (e.g., donepezil, memantine) that show some effectiveness; however, they only relieve symptoms. Two factors hamper research. First, the cause of Alzheimer’s disease is not fully understood. Second, the blood-brain barrier restricts drug efficacy. This review summarized current knowledge relevant to both of these factors. First, we reviewed the pathophysiology of Alzheimer’s disease. Next, we reviewed the structural and biological properties of the blood-brain barrier. We then described the most promising drug delivery systems that have been developed in recent years; these include polymeric nanoparticles, liposomes, metallic nanoparticles and cyclodextrins. Overall, we aim to provide ideas and clues to design effective drug delivery systems for penetrating the blood-brain barrier to treat Alzheimer’s disease.

BackgroundSabinene, one kind of monoterpene, accumulated limitedly in natural organisms, is being explored as a potential component for the next generation of aircraft fuels. And demand for advanced fuels impels us to develop biosynthetic routes for the production of sabinene from renewable sugar.ResultsIn this study, sabinene was significantly produced by assembling a biosynthetic pathway using the methylerythritol 4-phosphate (MEP) or heterologous mevalonate (MVA) pathway combining the GPP and sabinene synthase genes in an engineered Escherichia coli strain. Subsequently, the culture medium and process conditions were optimized to enhance sabinene production with a maximum titer of 82.18 mg/L. Finally, the fed-batch fermentation of sabinene was evaluated using the optimized culture medium and process conditions, which reached a maximum concentration of 2.65 g/L with an average productivity of 0.018 g h-1 g-1 dry cells, and the conversion efficiency of glycerol to sabinene (gram to gram) reached 3.49%.ConclusionsThis is the first report of microbial synthesis of sabinene using an engineered E. coli strain with the renewable carbon source as feedstock. Therefore, a green and sustainable production strategy has been established for sabinene.

The objective of this study was to evaluate the effects of isobutyrate supplementations on rumen fermentation, urinary excretion of purine derivatives and feed digestibility in steers. Eight ruminally cannulated Simmental steers were used in a replicated 4 x 4 Latin square experiment. On DM basis, diet consisted of 60% corn stover and 40% concentrate. Dry matter intake (averaged 9 kg/d) was restricted to 90% of ad libitum intake. The four treatment groups received a daily dose of 0 (control), 8.4, 16.8 or 25.2 g isobutyrate per steer. With increasing isobutyrate supplementation total VFA concentration (range 64.2-74.0 mM) was significantly enhanced. The ratio of acetate to propionate (range 2.72-4.25) was also significantly increased due to the increase in actate production and decrease in propionate production. With increasing isobutyrate supplementation the ruminal degradation of NDF from corn stover was improved but the CP degradability of soybean meal was decreased. Furthermore, the isobutyrate supplementation caused a significantly increased urinary excretion of purine derivatives. Similarly, digestibilities of OM, NDF and CP in the total tract were significantly increased. The present results indicate that dietary supplementation with isobutyrate improved rumen fermentation and feed digestion in beef cattle in a dose-dependent manner. According to the conditions of this experiment, the optimum daily dose of isobutyrate was about 16.8 g/animal.